Clinical trials: Patients With Cancer
Non-Squamous Non-Small Cell Lung Cancer
Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants
The purpose of this non-interventional study is the collection and documentation of data on safety and efficacy of intravenous (IV) bevacizumab (Avastin) in addition to platinum-based chemotherapy for first-line treatment in…
- Trial name
- NCT02596958
- Testing
- Bevacizumab
- Where
- Germany
- Volunteers
- 996 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Neoplasms
Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy
The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic…
- Trial name
- NCT03333655
- Testing
- Biopsy
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Familial Adenomatous Polyposis
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
This is a multicenter, two-part trial in participants with FAP.
- Trial name
- TUPELO (NCT05552755)
- Testing
- REC-4881
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Advanced Non-hematologic Malignancies, Advanced Metastatic Melanoma
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and maximum tolerated dose of TAK-733 in patients with advanced, nonhematologic tumors.
- Trial name
- NCT00948467
- Testing
- TAK-733
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients…
- Trial name
- RESONATE™ (NCT01578707)
- Testing
- ofatumumab, ibrutinib
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 391 people
- Sponsor
- Pharmacyclics LLC.
Malignant Tumors
A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors
This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.
- Trial name
- NCT06944444
- Testing
- SSS59
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
The purpose of this study is to estimate the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) regimen and characterize the pharmacokinetics (PK) of brigatinib monotherapy (film-coated tablets and age-appropriate…
- Conditions
- Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors
- Trial name
- NCT04260009
- Testing
- Brigatinib, Brigatinib AAF
- Sponsor
- Takeda
Tuberous Sclerosis Complex
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be…
- Trial name
- NCT02962414
- Testing
- everolimus
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Solid Advanced Tumor
Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the anti-EGFR/c-Met bispecific antibody MCLA-129 in combination with Ensartinib hydrochloride in…
- Trial name
- NCT07448116
- Testing
- MCLA-129, Ensartinib
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-hodgkin Lymphoma
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
The primary objective of this study is to determine the safety and tolerability of GS-0189 (formerly FSI-189) as monotherapy and in combination with rituximab in participants with relapsed/refractory (R/R) non-Hodgkin lymphoma…
- Trial name
- NCT04502706
- Testing
- GS-0189, Rituximab
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Gilead Sciences
Pancreatic Neoplasms
A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
The purpose of this study is to determine if imexon in combination with gemcitabine could improve overall survival as compared to gemcitabine alone in subjects with pancreatic cancer that has spread to other organs such as the…
- Trial name
- NCT00637247
- Testing
- imexon in combination with gemcitabine
- Where
- 48 sites in United States
- Volunteers
- 142 people
- Sponsor
- AmpliMed Corporation
Uveal Melanoma
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic…
- Trial name
- NCT02601378
- Testing
- LXS196, LXS196 and HDM201
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or…
- Trial name
- RAINFOL-03 (NCT07166094)
- Testing
- Rina-S, IC
- Where
- 178 sites in United States, Australia and 17 more
- Volunteers
- 660 people
- Sponsor
- Genmab
Malignant Pleural Mesothelioma
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
- Trial name
- NCT01098266
- Testing
- NGR-hTNF plus Best Investigator's Choice (BIC)
- Where
- 49 sites in United States, Belgium and 10 more
- Volunteers
- 400 people
- Sponsor
- AGC Biologics S.p.A.
Non Small Cell Lung Cancer
Performance Status During Treatment With Pemetrexed in Patients With NSCLC
The primary research objective of this observational study in pretreated patients with NSCLC of Stage IIIa/b or Stage IV is to evaluate patients' Karnofsky Index (KI) after the second cycle of second-line treatment with single…
- Trial name
- PERFORMANCE (NCT00540241)
- Testing
- Pemetrexed
- Where
- Germany
- Volunteers
- 542 people
- Sponsor
- Eli Lilly and Company
Metastatic Non-small Cell Lung Cancer
Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib
This study is a multi-center, open-label, dose-finding phase Ib clinical study with extension phase, which is aimed at evaluating the efficacy and safety of GB226 combined with fruquintinib in treatment of relapsed or metastatic…
- Trial name
- NCT03976856
- Testing
- GB226, Fruquintinib
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Genor Biopharma Co., Ltd.
Pancreatic Cancer
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new…
- Trial name
- NCT00401570
- Testing
- Volociximab, Gemcitabine
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Adult, Lung Cancer
Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) for treatment of patients with Advanced lung cancer,while evaluating…
- Trial name
- NCT06519669
- Testing
- GT201 injection
- Where
- 2 sites in China
- Volunteers
- 2 people
- Sponsor
- Grit Biotechnology
Advanced Gastric Cancer
Efficacy Study of TKcell in Advanced Gastric Cancer
The purpose of this study is to determine efficacy of NKCell combined FOLFOX-4 chemotherapy in gastric cancer
- Trial name
- NCT00854854
- Testing
- TKCell
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Binex
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.